Hyperoside could rectify bone metabolism disorder in ovariectomized mice, which was related to the inhibition of the TRAF-6 mediated RANKL/RANK/NF-κB signaling pathway and the elevation of the OPG/RANKL ratio [41]. The gene discussed is TNFRSF11B; the disease is metabolic bone disorder.